Agenus reported $33.7M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 17.4B 410M Sep/2026
Agenus USD 33.7M 500K Mar/2026
Amgen USD 10.4B 300M Sep/2026
AstraZeneca USD 16.21B 830M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Celldex Therapeutics USD 400K 378K Sep/2026
CSL USD 8.33B 4.79B Dec/2025
Eli Lilly USD 24.4B 1.43B Sep/2026
Gilead Sciences USD 8.3B 500M Sep/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
Glaxosmithkline GBP 8.89B 1.2B Sep/2026
Incyte USD 1.56B 110M Sep/2026
Intrexon USD 717K 511K Jun/2024
J&J USD 25.4B 89M Sep/2026
Jiangsu Hengrui CNY 8.95B 320M Sep/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
MacroGenics USD 32.83M 12.03M Jun/2026
Merck EUR 5.63B 200M Sep/2026
Merck USD 18.1B 1.5B Sep/2026
Northwest Biotherapeutics USD 494K 294K Mar/2026
Novartis USD 14.52B 112M Sep/2026
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 16.6B 1.57B Sep/2026
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Veracyte USD 151.75M 1.43M Sep/2026